BCL2L1 and melanoma: Trametinib-resistant melanoma cells grown with or without trametinib did not respond with substantial apoptotic death to ABT-263 or ABT-199 in our study indicating that these cells did not rely on anti-apoptotic proteins BCL-2, BCL-XL, and/or BCL-w.